Research programme: leishmaniasis therapies - WHO/Tibotec

Drug Profile

Research programme: leishmaniasis therapies - WHO/Tibotec

Alternative Names: Leishmaniasis therapies research programme - WHO/Tibotec; PX 6518; Research programme: saponins - WHO/Tibotec; Saponins research programme - WHO/Tibotec

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator World Health Organization
  • Developer Janssen Infectious Diseases BVBA
  • Class Triterpenes
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Visceral leishmaniasis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Visceral-leishmaniasis in Belgium
  • 20 Feb 2008 No development reported - Preclinical for Visceral leishmaniasis in Belgium (unspecified route)
  • 10 Mar 2004 Preclinical trials in Visceral leishmaniasis in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top